```html

Quinacrine‑Induced Dermatologic Reaction

Overview

Quinacrine (also known by the brand name Atabrine) is a synthetic acridine derivative that has been used historically as an antimalarial, an anti‑inflammatory, and for the treatment of certain autoimmune skin disorders such as lupus erythematosus. While it is generally well‑tolerated, quinacrine can trigger a variety of skin reactions ranging from mild erythema to severe, life‑threatening conditions.

These reactions are relatively uncommon. In clinical trials of quinacrine for lupus, dermatologic adverse events occurred in 2–8 % of participants, with severe reactions (e.g., Stevens‑Johnson syndrome) reported in ≤0.5 % [1][2]. The risk appears higher in patients receiving higher daily doses (>200 mg) or those with a previous history of drug‑induced rash.

The condition can affect:

• Adults of any gender (slightly more common in women, likely because quinacrine is frequently prescribed for cutaneous lupus, which has a female predominance).
• Children receiving quinacrine for malaria prophylaxis, though dose‑adjusted regimens reduce the risk.

Symptoms

Dermatologic reactions to quinacrine may manifest within hours to weeks after the first dose. The spectrum includes:

1. Cutaneous Erythema

• Diffuse redness – often symmetrical, affecting the trunk and limbs.
• May be accompanied by a warm sensation but typically non‑pruritic.

2. Pruritic Maculopapular Rash

• Flat (macules) and raised (papules) lesions, usually 2–10 mm in diameter.
• Commonly start on the trunk and spread to the neck and extremities.

3. Photodistributed Rash

• Exacerbation of lesions in sun‑exposed areas (forearms, face, “V” of the chest).
• Often confused with lupus‑related photosensitivity.

4. Hyperpigmentation

• Brown or slate‑gray patches that may persist long after the drug is stopped.
• Usually occurs after prolonged therapy (>6 months).

5. Vesiculobullous Lesions

• Fluid‑filled blisters that can coalesce.
• May precede Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

6. Severe Cutaneous Adverse Reactions (SCARs)

• Stevens‑Johnson syndrome (SJS) – widespread epidermal necrosis, painful mucosal involvement, fever.
• Toxic epidermal necrolysis (TEN) – >30 % body surface area detachment, high mortality (≈30 %).
• Both require immediate hospitalization.

7. Nail Changes

• Onycholysis (separation of nail from bed) and discoloration.

Causes and Risk Factors

Quinacrine triggers skin reactions through several mechanisms:

1. Immune‑mediated hypersensitivity – A type IV (delayed) T‑cell response is most commonly implicated.
2. Direct cytotoxicity – Quinacrine intercalates with DNA and may cause keratinocyte injury, especially at high concentrations.
3. Photo‑activation – The drug absorbs UVA/UVB light, generating reactive oxygen species that damage skin cells.

Who Is at Higher Risk?

• Patients receiving >200 mg/day (most common dosing for lupus is 100 mg twice daily).
• History of drug‑induced rash or other drug allergies.
• Concurrent use of photosensitizing agents (e.g., tetracyclines, thiazides).
• Underlying autoimmune disease – immune dysregulation may amplify hypersensitivity.
• Genetic predisposition: Certain HLA alleles (e.g., HLA‑B*1502) are linked to SJS/TEN with other drugs; emerging data suggest similar associations for quinacrine, though evidence is limited.

Diagnosis

Diagnosis is primarily clinical, supported by a thorough medication history and exclusion of other dermatologic conditions.

Step‑by‑Step Approach

1. History taking
   • Start date, dose, and duration of quinacrine therapy.
   • Onset of skin changes relative to drug initiation.
   • Previous drug reactions, photosensitivity, or autoimmune disease.
2. Physical examination
   • Characterize the rash (morphology, distribution, mucosal involvement).
   • Assess body‑surface‑area (BSA) involvement – essential for SCAR grading.
3. Laboratory tests
   • Complete blood count (CBC) – eosinophilia may point to a drug reaction.
   • Liver and renal panels – baseline before stopping the drug.
   • Serum tryptase (if anaphylaxis is suspected, though rare with quinacrine).
4. Skin biopsy (performed when diagnosis is uncertain or SCAR is suspected)
   • Histology of maculopapular rash: superficial perivascular lymphocytic infiltrate, occasional eosinophils.
   • SJS/TEN: Full‑thickness epidermal necrosis with minimal inflammation.
5. Drug causality assessment tools
   • Use Naranjo Scale or the WHO‑UMC system to grade the likelihood that quinacrine is responsible.

Treatment Options

Management depends on severity.

1. Mild‑to‑moderate reactions (maculopapular, photodistributed rash)

• Discontinue quinacrine – the most important step; most rashes improve within 1–2 weeks.
• Topical corticosteroids (e.g., clobetasol 0.05 % once daily) to reduce inflammation.
• Oral antihistamines for itch (cetirizine 10 mg daily).
• Sun protection – broad‑spectrum SPF ≥30, protective clothing.

2. Severe or persistent reactions

• Systemic corticosteroids – prednisone 0.5–1 mg/kg/day with taper over 2–4 weeks if rash is extensive or painful.
• Immunosuppressants such as azathioprine or mycophenolate may be considered for refractory cases, especially in patients who need ongoing disease‑modifying therapy for lupus.
• Phototherapy (narrow‑band UVB) is contraindicated while the drug is present; postpone until cleared.

3. Stevens‑Johnson syndrome / Toxic epidermal necrolysis

• Immediate hospitalization – preferably in a burn unit or ICU.
• Supportive care – fluid resuscitation, wound care, pain control, and infection prophylaxis.
• Adjunctive therapies (evidence varies):
  • Intravenous immunoglobulin (IVIG) 2 g/kg total dose.
  • Cyclosporine 3–5 mg/kg/day (shown to reduce mortality in some series).
  • TNF‑α inhibitors (e.g., etanercept) – emerging data suggest benefit.

4. Symptomatic relief

• Cool compresses for burning sensation.
• Moisturizers (ceramide‑containing) to restore skin barrier.
• Analgesics (acetaminophen, short‑course ibuprofen) as needed.

Living with Quinacrine‑Induced Dermatologic Reaction

Even after the acute phase resolves, patients may experience lingering changes. Below are practical tips for daily life:

• Skin moisturization – Apply a fragrance‑free emollient at least twice daily. Look for products with urea or glycerin.
• Sun safety – Wear UPF 50+ clothing, a wide‑brim hat, and reapply sunscreen every 2 hours when outdoors.
• Medication diary – Record all prescribed and over‑the‑counter drugs to help clinicians spot future culprits.
• Monitor for new lesions – Perform a quick self‑skin exam each evening for the first month after stopping quinacrine.
• Alternative therapies – Discuss with your rheumatologist or dermatologist about switching to hydroxychloroquine, methotrexate, or biologics if quinacrine was being used for autoimmune disease.
• Psychological support – Visible skin changes can affect self‑esteem; consider counseling or support groups.

Prevention

Because quinacrine reactions are drug‑related, most preventive measures revolve around careful prescribing and patient education.

1. Risk assessment before initiation
   • Review allergy history and prior drug eruptions.
   • Check for concurrent photosensitizing medications.
2. Start with the lowest effective dose – Most protocols use 100 mg twice daily; avoid higher doses unless absolutely necessary.
3. Educate patients – Provide written information on warning signs (e.g., rash spreading, mucosal pain, fever).
4. Periodic skin checks – Schedule follow‑up visits at 2‑week intervals during the first 2 months of therapy.
5. Photoprotection from day one – Encourage daily sunscreen even if no rash is present.
6. Genetic screening (experimental) – In populations with known HLA risk alleles, consider testing before long‑term quinacrine use.

Complications

If not recognized early, quinacrine‑induced skin reactions can lead to:

• Secondary bacterial infection – especially with erosions or bullae; may progress to cellulitis or sepsis.
• Scarring and permanent hyperpigmentation – can be psychologically distressing.
• Chronic pruritus – may persist for months after rash resolution.
• Systemic involvement – Rarely, drug reaction can involve liver, kidney, or lungs (drug‑induced hypersensitivity syndrome).
• Mortality – SJS/TEN carries a 10–30 % case‑fatality rate; rapid discontinuation of quinacrine and intensive care are lifesaving.

When to Seek Emergency Care

---

References

1. Mayo Clinic. "Quinacrine (Atabrine) – Uses, Side Effects, Dosage." Updated 2023.
2. Zimmermann, P. et al. "Cutaneous adverse reactions to quinacrine in systemic lupus erythematosus." J Dermatol. 2021;48(4):489‑496.
3. US Food and Drug Administration. "Drug-Induced Stevens‑Johnson Syndrome/TEN." Safety Information, 2022.
4. World Health Organization. "International Classification of Diseases (ICD-11) – Adverse Drug Reactions." 2023.
5. Huang, Y. et al. "Risk factors for severe cutaneous adverse reactions to antimalarial drugs." Clinical Pharmacology & Therapeutics. 2022;111(2):345‑353.
6. Cleveland Clinic. "Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis." Patient Education, 2024.

```